2[1]Liebowitz LD, Ashbee HR, Evans EG, et al. A two year global evaluation of the susceptibility of Candida species to fluconazole by disk diffusion[J]. Diagn Microbiol Infect Dis, 2001, 40: 27-33 被引量：1
3Wenzel R, Brewer TF, Butzler JP,et al. Fungi, A guide to infection control in the hospital(2nd Edition),international society for infection diseases[M]. Boston,MA.USA, BC Decker Inc Hamilton. London, 2002, 157-159 被引量：1
4National Committee for Clinical Laboratory Standards. Method for antifungal disk diffusion susceptibility testing of yeasts; proposed guideline[S]. NCCLS M44-P, 2003, 123: 6 被引量：1
5Berke I, Tierno PM Jr. Comparison of efficacy and cost-effectiveness of BIOMIC video and Vitek antimicrobial susceptibility test systems for use in the clinical microbiology laboratory[J]. J Clinical Microbiology,1996, 34:1980-1984 被引量：1
6Rangel-Frausto MS, Wiblin T, Blumberg HM,et al. National Epidemiology of Mycoses Survey. Variations in rates of Candida Bloodstream Infections due to candida species in Seven surgical ICUs and six Neonatal ICUs[J]. Clin Infect Dis 1999, 29:253-258 被引量：1
7Edmond MB,Wallace SE, McClish DK, et al. Nosocomial bloodstream infections in United States Hospitals: a three-year analysis[J]. Clin Infect Dis,1999, 29:239-244 被引量：1
8Beck-Sague C, Jarvis WR. Secular trends in the epidemiology of nosocomial fungal infections in the United States,1980-1990[J].J Infect Dis ,1993,167:1247-1251 被引量：1
9Pfaller MA, Jones RN, Doern GV, et al. International surveillance of bloodstream infections due to Candida species: frequency of occurrence and antifungal susceptibilities of isolates collected in 1997 in the United States, Canada, and South America for the SENTRY program[J]. J Clin Microbiol ,1998, 36:1886-1889 被引量：1
10Paterson PJ, McWhinney PH, Potter M, et al. The combination of oral amphotericin B with azoles prevents the emergence of resistant Candida species in neutropenic patients[J]. Br J Haemotol, 2001,112:175-180 被引量：1
